Logo image of XXII

22ND CENTURY GROUP INC (XXII) Stock Fundamental Analysis

NASDAQ:XXII - Nasdaq - US90137F3010 - Common Stock

5.13  -0.6 (-10.47%)

After market: 5.0255 -0.1 (-2.04%)

Fundamental Rating

2

Overall XXII gets a fundamental rating of 2 out of 10. We evaluated XXII against 8 industry peers in the Tobacco industry. XXII has a bad profitability rating. Also its financial health evaluation is rather negative. XXII has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

XXII had negative earnings in the past year.
In the past year XXII has reported a negative cash flow from operations.
In the past 5 years XXII always reported negative net income.
In the past 5 years XXII always reported negative operating cash flow.
XXII Yearly Net Income VS EBIT VS OCF VS FCFXXII Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

XXII has a Return On Assets of -216.65%. This is amonst the worse of the industry: XXII underperforms 87.50% of its industry peers.
XXII has a Return On Equity of -1633.47%. This is in the lower half of the industry: XXII underperforms 62.50% of its industry peers.
Looking at the Return On Invested Capital, with a value of 306.57%, XXII belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
ROA -216.65%
ROE -1633.47%
ROIC 306.57%
ROA(3y)-214.42%
ROA(5y)-143.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XXII Yearly ROA, ROE, ROICXXII Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1K -1K

1.3 Margins

XXII has a Operating Margin of 1896.54%. This is amongst the best in the industry. XXII outperforms 100.00% of its industry peers.
XXII does not have Profit Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM 1896.54%
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XXII Yearly Profit, Operating, Gross MarginsXXII Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300 -400

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), XXII is creating value.
XXII has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, XXII has more shares outstanding
Compared to 1 year ago, XXII has a worse debt to assets ratio.
XXII Yearly Shares OutstandingXXII Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M 2.5M
XXII Yearly Total Debt VS Total AssetsXXII Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

XXII has an Altman-Z score of -14.84. This is a bad value and indicates that XXII is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -14.84, XXII is doing worse than 75.00% of the companies in the same industry.
XXII has a Debt/Equity ratio of 1.59. This is a high value indicating a heavy dependency on external financing.
XXII's Debt to Equity ratio of 1.59 is on the low side compared to the rest of the industry. XXII is outperformed by 62.50% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.59
Debt/FCF N/A
Altman-Z -14.84
ROIC/WACC57.84
WACC5.3%
XXII Yearly LT Debt VS Equity VS FCFXXII Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M

2.3 Liquidity

XXII has a Current Ratio of 1.09. This is a normal value and indicates that XXII is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.09, XXII is in line with its industry, outperforming 50.00% of the companies in the same industry.
XXII has a Quick Ratio of 1.09. This is a bad value and indicates that XXII is not financially healthy enough and could expect problems in meeting its short term obligations.
XXII has a better Quick ratio (0.93) than 62.50% of its industry peers.
Industry RankSector Rank
Current Ratio 1.09
Quick Ratio 0.93
XXII Yearly Current Assets VS Current LiabilitesXXII Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

2

3. Growth

3.1 Past

The earnings per share for XXII have decreased strongly by -76.90% in the last year.
XXII shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -94.97%.
The Revenue has been growing slightly by 4.03% on average over the past years.
EPS 1Y (TTM)-76.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25.97%
Revenue 1Y (TTM)-94.97%
Revenue growth 3Y4.64%
Revenue growth 5Y4.03%
Sales Q2Q%-66.62%

3.2 Future

Based on estimates for the next years, XXII will show a very strong growth in Earnings Per Share. The EPS will grow by 36.71% on average per year.
Based on estimates for the next years, XXII will show a very negative growth in Revenue. The Revenue will decrease by -34.43% on average per year.
EPS Next Y82.92%
EPS Next 2Y36.71%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-58.25%
Revenue Next 2Y-34.43%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
XXII Yearly Revenue VS EstimatesXXII Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
XXII Yearly EPS VS EstimatesXXII Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5K -10K -15K

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

XXII reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year XXII is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XXII Price Earnings VS Forward Price EarningsXXII Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

100.00% of the companies in the same industry are more expensive than XXII, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.12
XXII Per share dataXXII EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80 -100

4.3 Compensation for Growth

A more expensive valuation may be justified as XXII's earnings are expected to grow with 36.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.71%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

XXII does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

22ND CENTURY GROUP INC

NASDAQ:XXII (1/22/2025, 4:32:18 PM)

After market: 5.0255 -0.1 (-2.04%)

5.13

-0.6 (-10.47%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryTobacco
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst Owners0.75%
Inst Owner Change0%
Ins Owners21.41%
Ins Owner Change0.18%
Market Cap2.82M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-18.45%
Min Revenue beat(2)-31.87%
Max Revenue beat(2)-5.03%
Revenue beat(4)0
Avg Revenue beat(4)-33.68%
Min Revenue beat(4)-61.52%
Max Revenue beat(4)-5.03%
Revenue beat(8)1
Avg Revenue beat(8)-31.25%
Revenue beat(12)2
Avg Revenue beat(12)-21.11%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.17
P/FCF N/A
P/OCF N/A
P/B 0.81
P/tB N/A
EV/EBITDA 0.12
EPS(TTM)-118.88
EYN/A
EPS(NY)-15.57
Fwd EYN/A
FCF(TTM)-29.32
FCFYN/A
OCF(TTM)-26.82
OCFYN/A
SpS4.37
BVpS6.31
TBVpS-4.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -216.65%
ROE -1633.47%
ROCE 388.07%
ROIC 306.57%
ROICexc 562.5%
ROICexgc 5347.47%
OM 1896.54%
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-214.42%
ROA(5y)-143.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 1.59
Debt/FCF N/A
Debt/EBITDA 0.12
Cap/Depr 106.84%
Cap/Sales 57.2%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.09
Quick Ratio 0.93
Altman-Z -14.84
F-Score2
WACC5.3%
ROIC/WACC57.84
Cap/Depr(3y)127.65%
Cap/Depr(5y)92.29%
Cap/Sales(3y)10.61%
Cap/Sales(5y)7.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-76.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25.97%
EPS Next Y82.92%
EPS Next 2Y36.71%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-94.97%
Revenue growth 3Y4.64%
Revenue growth 5Y4.03%
Sales Q2Q%-66.62%
Revenue Next Year-58.25%
Revenue Next 2Y-34.43%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y167.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year92.55%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y60.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.43%
OCF growth 3YN/A
OCF growth 5YN/A